(Q30011021)

22 May 2017

title

Tadalafil dosed once a day in men with erectile dysfunction: a randomized, double-blind, placebo-controlled study in the US. (English)

1 reference

22 May 2017

0 references

1 reference

United States of America

1 reference

Rajfer J

1

1 reference

22 May 2017

Aliotta PJ

2

1 reference

22 May 2017

Steidle CP

3

1 reference

22 May 2017

Fitch WP 3rd

4

1 reference

22 May 2017

Zhao Y

5

1 reference

22 May 2017

Yu A

6

1 reference

22 May 2017

language of work or name

1 reference

27 July 2006

1 reference

International Journal of Impotence Research

22 May 2017

published in

1 reference

22 May 2017

volume

19

1 reference

22 May 2017

issue

1

1 reference

22 May 2017

page(s)

95-103

1 reference

Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group

22 May 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Tadalafil pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Efficacy and safety of daily tadalafil in men with erectile dysfunction previously unresponsive to on-demand tadalafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

The psychological and interpersonal relationship scales: assessing psychological and relationship outcomes associated with erectile dysfunction and its treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Sensitivity of the psychological and interpersonal relationship scales to oral therapies for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Phosphodiesterase type 5 is not upregulated by tadalafil in cultures of human penile cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Up and down-regulation of phosphodiesterase-5 as related to tachyphylaxis and priapism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

Tolerance to the therapeutic effect of tadalafil does not occur during 6 months of treatment: A randomized, double-blind, placebo-controlled study in men with erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

The efficacy and safety of tadalafil: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

7 January 2021

inferred from DOI database lookup

Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

7 January 2021

inferred from DOI database lookup

A 15-item short form of the psychological and interpersonal relationship scales

1 reference

https://api.crossref.org/works/10.1038%2FSJ.IJIR.3901496

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/SJ.IJIR.3901496

1 reference

Dimensions Publication ID

22 May 2017

1050435486

0 references

Fatcat ID

release_lqbnjq2wkbc7bda5i3r4tl4rdu

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/lqbnjq2wkbc7bda5i3r4tl4rdu

24 November 2022

mapped directly with Wikidata item

1 reference